GemOx
(Redirected from GEMOX)
GemOx or GEMOX is an acronym for one of the chemotherapy regimens used in the treatment of relapsed or primary refractory non-Hodgkin lymphoma and Hodgkin lymphoma.
When combined with Rituximab it is called R-GemOx, R-GEMOX or GemOx-R, GEMOX-R.
The [R]-GemOx regimen consists of:
- Rituximab - anti-CD20 monoclonal antibody that has the ability to kill both normal and malignant B cells;
- Gemcitabine - an antimetabolite;
- Oxaliplatin - a platinum-based alkylating antineoplastic agent.[1][2]
Dosing regimen
[edit | edit source]| Drug | Dose | Mode | Days |
|---|---|---|---|
| Rituximab | 375 mg/m2 | IV infusion | Day 1 |
| Gemcitabine | 1000 mg/m2 | IV infusion in 500 ml normal saline with the speed of 10 mg/m2/min | Day 2 |
| Oxaliplatin | 100 mg/m2 | IV infusion over 2hrs | Day 2 |
References
[edit | edit source]- ^ GEMOX-R regimen is a highly effective salvage regimen in patients with refractory / relapsing diffuse large-cell lymphoma: a phase II study
- ^ Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy